The incidence of diabetes is growing rapidly both in India and worldwide. Dapagliflozin is a drug of the gliflozin class which is a sodium-glucose cotransporter – inhibitor (SGLT-2), which prevent glucose reabsorption in the kidney. The present investigation is concerned with method development and validation of simple, precise, accurate, reproducible and specific reversed-phase high-performance liquid chromatography (RP-HPLC) method for estimation of Dapagliflozin in bulk and pharmaceutical dosage form using an INERTSIL ODS-2 C18 column (250mm x 4.6mm x 5µ) column in isocratic mode with 0.01 M Ammonium Formate Buffer (pH 3.5): Acetonitrile (50:50 v/v) as mobile phase at a flow rate of 1ml/min. The determination of analyte was carried out at 224nm using a PDA detector. The retention time for Dapagliflozin was found to be 4.7 min. The proposed method has permitted the quantification of Dapagliflozin over linearity in the range of 1.25 – 3.75 µg/ml and its mean recovery were found to be 99.91%. The % RSD of intraday and interday precision were found 0.40% and 0.46%. The proposed method was applied successfully for the determination of Dapagliflozin in a pharmaceutical dosage form.